

## [New Drug Approvals](#)

### Generic Name (Trade Name—Company)

May 27, 2011

### Uses/Notes

Treatment of adult patients with *Clostridium difficile*-associated diarrhea

### Fidaxomicin

(*Dificid—Optimer*)

Treatment of *Clostridium difficile*-associated diarrhea

[Fidaxomicin](#), formerly known as OPT-80, is primarily active against species of clostridia, including *C. difficile*, and works by inhibiting bacterial protein synthesis via transcription inhibition. A key advantage of fidaxomicin over currently available treatments is that this agent is thought to have less deleterious effects on intestinal microbiota, resulting in a lower rate of recurrent infections. The recommended dose is 200 mg twice daily for 10 days. When compared with vancomycin, fidaxomicin was found to be noninferior in terms of clinical response, but was associated

with a better sustained response.

### Source URL:

<http://aphanet.org/treatment-clostridium-difficile-associated-diarrhea>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.